Related Experiment Video

Updated: Aug 4, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Neuropsychiatric toxicity associated with cytokine therapies

D M Lerner1, A Stoudemire, D L Rosenstein

  • 1Experimental Therapeutics Branch, National Institute of Mental Health, Bethesda, MD 20892-1274, USA.

Psychosomatics
|September 10, 1999
PubMed

Insights

Interleukin-2 and interferon-alpha therapies, while effective for various diseases, can cause limiting neuropsychiatric side effects. Understanding and managing these central nervous system toxicities is crucial for patient care.

Area of Science:

  • Immunology
  • Neuroscience
  • Oncology

Background:

  • Interleukin-2 (IL-2) and interferon-alpha (IFN-α) are critical biologic agents for treating cancers, infections, and neurodegenerative conditions.
  • A significant challenge limiting the use of IL-2 and IFN-α is their associated neuropsychiatric toxicity.
  • The mechanisms underlying these central nervous system (CNS) adverse effects are not fully understood, leading to frequent misdiagnosis.

Purpose of the Study:

  • To review the existing preclinical and clinical literature on the neuropsychiatric toxicities of IL-2 and IFN-α.
  • To delineate the morbidity associated with these biologic agents.
  • To propose clinical management strategies and identify future research directions.

Main Methods:

  • Comprehensive literature search of preclinical and clinical studies.
  • Analysis of reported cases and experimental data on IL-2 and IFN-α induced neurotoxicity.
  • Synthesis of findings to inform clinical practice and research.

Main Results:

  • Documented evidence of significant neuropsychiatric adverse events linked to IL-2 and IFN-α therapy.
  • Identification of common CNS manifestations and potential pathophysiological pathways.
  • Highlighting diagnostic challenges and the need for specialized clinical awareness.

Conclusions:

  • Neuropsychiatric toxicity is a critical dose-limiting factor for IL-2 and IFN-α therapies.
  • Improved understanding of pathophysiology is needed for accurate diagnosis and effective management.
  • Further research is essential to develop targeted interventions and optimize patient outcomes.

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

Microfluidic Approach to Resolve Simultaneous and Sequential Cytokine Secretion of Individual Polyfunctional Cells09:43

Microfluidic Approach to Resolve Simultaneous and Sequential Cytokine Secretion of Individual Polyfunctional Cells

Published on: March 8, 2024

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...